Thermo Fisher Scientific CD11a (LFA-1alpha) Monoclonal Antibody (HI111), FITC, eBioscience

Applications

Immunohistochemistry (IHC)

• Tested Dilution: Not specified
• Publications: View 1 publication

Flow Cytometry (Flow)

• Tested Dilution: 5 µL (1 µg)/test
• Publications: View 4 publications

Product Specifications

Additional Formats

• Unconjugated
• Functional Grade
• NovaFluor Blue 610-70S
• NovaFluor Red 710
• NovaFluor Red 725
• NovaFluor Yellow 660
• NovaFluor Yellow 755
• Request custom conjugation

Product Specific Information

The HI111 monoclonal antibody reacts with human CD11a, the 180 kDa integrin alphaL, also known as lymphocyte function-associated antigen-1 (LFA-1) alpha chain. LFA-1, formed by non-covalent association of CD11a with CD18 (integrin beta2), serves as an important adhesion molecule involved in lymphocyte and granulocyte function. CD54 (ICAM-1), CD102 (ICAM-2), and CD50 (ICAM-3) are ligands for LFA-1. CD11a is expressed by all leukocytes.

Applications Reported:

• Flow cytometric analysis.

Applications Tested:

• Pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells.
• Use at 5 µL (1 µg) per test (defined as the amount of antibody for staining in 100 µL final volume).
• Cell number: 10⁵–10⁸ cells/test (empirically determined).

Excitation: 488 nm
Emission: 520 nm
Laser: Blue Laser
Filtration: 0.2 µm post-manufacturing filtered

Target Information

CD11a (LFA-1 alpha, ITGAL) together with CD18 constitute leukocyte function-associated antigen 1 (LFA-1), the αLβ2 integrin. CD11a is implicated in activation of the LFA-1 complex and plays a central role in leukocyte intercellular adhesion through interactions with ICAM-1, -2, and -3. It also functions in lymphocyte costimulatory signaling.

CD11a is expressed on leukocyte plasma membranes in a low-affinity conformation; upon stimulation, it shifts to a high-affinity state enabling tight ligand binding. It participates in immune cell interactions, tissue-specific migration, and regulation of T-cell effector functions.

Blocking CD11a function is a therapeutic strategy for inflammatory diseases. For example, the humanized anti-CD11a antibody Efalizumab (Raptiva) inhibits T cell migration, while simvastatin binding to CD11a modulates immune activity. Two transcript variants encoding different isoforms have been identified. Diseases associated with CD11a dysfunction include benign cephalic histiocytosis and leukocyte adhesion deficiency.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

제품 이미지